These results suggest that a CCR5 inhibitor may provide the possibility of a novel therapeutic strategy for CRC, and that serum levels of CCL3 and CCL4 could be predictive biomarkers for the prognosis of CRC patients. This evidence concerns the gene CCL4 and colorectal carcinoma.